| Not Yet Recruiting | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults NCT07516353 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma NCT07514819 | St. Jude Children's Research Hospital | N/A |
| Not Yet Recruiting | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maint NCT07466316 | Children's Oncology Group | Phase 3 |
| Not Yet Recruiting | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors NCT07224568 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190 | University of Florida | Phase 1 / Phase 2 |
| Not Yet Recruiting | Tumor-Lymph Node Mapping NCT07054944 | University of Rochester | Phase 1 |
| Recruiting | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABR NCT07172958 | Children's National Research Institute | Phase 1 |
| Not Yet Recruiting | A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatm NCT07355855 | Fudan University | Phase 2 |
| Recruiting | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-speci NCT07148050 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in P NCT06441331 | ITM Solucin GmbH | Phase 1 |
| Recruiting | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdo NCT06865664 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells NCT06198296 | Baylor College of Medicine | Phase 1 |
| Not Yet Recruiting | Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma NCT06932861 | Xinxin Zhang | EARLY_Phase 1 |
| Recruiting | Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma NCT06796543 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Recruiting | Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Thr NCT06924463 | Lille University | — |
| Active Not Recruiting | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer NCT06521567 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Not Yet Recruiting | Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models NCT06822842 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomi NCT06709495 | David S Shulman, MD | Phase 1 / Phase 2 |
| Recruiting | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of R NCT06684327 | Fudan University | Phase 2 |
| Recruiting | Ivonescimab in the Treatment of Multiple Advanced Tumors NCT06683846 | Fudan University | Phase 2 |
| Suspended | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Ref NCT04890093 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors NCT06541262 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials NCT06029465 | Power Life Sciences Inc. | — |
| Recruiting | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen NCT06456892 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatri NCT04715191 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants NCT06566092 | Iovance Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Bas NCT06023641 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) NCT06094101 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Recruiting | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors NCT04796012 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Withdrawn | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors NCT04791228 | Children's National Research Institute | Phase 2 |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Withdrawn | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800 | Brown University | Phase 2 |
| Completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors NCT05302921 | Children's National Research Institute | Phase 2 |
| Recruiting | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced NCT04995003 | Baylor College of Medicine | Phase 1 |
| Completed | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With NCT05093322 | Hutchmed | Phase 1 / Phase 2 |
| Recruiting | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Sol NCT04337177 | Valent Technologies, LLC | Phase 1 |
| Withdrawn | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876 | Brown University | Phase 2 |
| Active Not Recruiting | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid NCT04377932 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid NCT05103631 | Baylor College of Medicine | Phase 1 |
| Terminated | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and You NCT04730349 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Indo-cyanine Green (ICG) in Paediatric Oncology MIS NCT04854018 | Birmingham Women's and Children's NHS Foundation Trust | Phase 4 |
| Completed | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers NCT05697198 | Labcorp Corporation of America Holdings, Inc | — |
| Active Not Recruiting | Evolutionary Therapy for Rhabdomyosarcoma NCT04388839 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Drug Sensitivity and Mutation Profiling NCT04956198 | Florida International University | — |
| Recruiting | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma NCT04625907 | University of Birmingham | Phase 1 / Phase 2 |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdom NCT04299113 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tu NCT04095221 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680 | Pfizer | Phase 2 |
| Active Not Recruiting | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and NCT03478462 | Cellectar Biosciences, Inc. | Phase 1 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Terminated | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients NCT03458728 | Bayer | Phase 1 / Phase 2 |
| Active Not Recruiting | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) NCT03496402 | Institut Curie | N/A |
| Completed | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in NCT03245450 | Eisai Inc. | Phase 1 / Phase 2 |
| Unknown | Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old NCT03462888 | Centre Oscar Lambret | — |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family NCT03041701 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Enrolling By Invitation | Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas NCT03054792 | The Hospital for Sick Children | Phase 1 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Recruiting | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies NCT04308330 | New York Medical College | Phase 1 |
| Recruiting | A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors. NCT06836492 | Yizhuo Zhang | Phase 3 |
| Terminated | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms T NCT02581384 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors NCT02982941 | MacroGenics | Phase 1 |
| Withdrawn | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Soli NCT02557854 | Theodore Laetsch | Phase 1 |
| Completed | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma NCT02945800 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumor NCT02536183 | AeRang Kim | Phase 1 |
| Completed | Impact of an Orthotic Intervention in Children With Peripheral Neuropathy NCT03655587 | Children's Hospitals and Clinics of Minnesota | N/A |
| Withdrawn | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors NCT02689336 | Washington University School of Medicine | Phase 2 |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Active Not Recruiting | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosar NCT02567435 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and S NCT02508038 | University of Wisconsin, Madison | Phase 1 |
| Completed | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarc NCT02509598 | Cardinal Health 414, LLC | Phase 2 |
| Completed | Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sar NCT02415816 | St. Jude Children's Research Hospital | N/A |
| Completed | Trial of Afatinib in Pediatric Tumours NCT02372006 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Completed | TAA-Specific CTLS for Solid Tumors (TACTASOM) NCT02239861 | Baylor College of Medicine | Phase 1 |
| Completed | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors NCT02390843 | Emory University | Phase 1 |
| Unknown | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas NCT02409576 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Completed | Molecular-Guided Therapy for Childhood Cancer NCT02162732 | Giselle Sholler | N/A |
| Completed | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes NCT02048371 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Withdrawn | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02011126 | Children's Oncology Group | Phase 2 |
| Completed | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors NCT02076906 | AeRang Kim | Phase 1 |
| Active Not Recruiting | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabd NCT01871766 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With NCT01962103 | Celgene | Phase 1 / Phase 2 |
| Unknown | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophos NCT02013336 | South Plains Oncology Consortium | Phase 1 |
| Withdrawn | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma NCT01697514 | Eli Lilly and Company | Phase 1 |
| Completed | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma NCT01858168 | Massachusetts General Hospital | Phase 1 |
| Unknown | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors NCT01807468 | Samsung Medical Center | Phase 2 |
| Terminated | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors NCT02100891 | Monica Thakar | Phase 2 |
| Completed | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors NCT01661400 | Washington University School of Medicine | Phase 1 |
| Completed | Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy NCT01674101 | St. Jude Children's Research Hospital | N/A |
| Completed | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory S NCT01625351 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma NCT01614795 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdo NCT01355445 | Centre Oscar Lambret | Phase 2 |
| Completed | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors NCT01505569 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI NCT01336803 | Heike E Daldrup-Link | Phase 2 |
| Completed | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors NCT01331135 | Emory University | Phase 1 |
| Completed | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminar NCT01125800 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients NCT01169584 | Jennerex Biotherapeutics | Phase 1 |
| Completed | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma NCT01241162 | University of Louisville | Phase 1 |
| Withdrawn | Markers of Anthracycline-Related Cardiac Muscle Injury NCT01112800 | St. Jude Children's Research Hospital | — |
| Completed | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors NCT00931931 | Timothy Cripe | Phase 1 |
| Active Not Recruiting | Methionine PET/CT Studies In Patients With Cancer NCT00840047 | St. Jude Children's Research Hospital | Phase 2 |
| Withdrawn | A Vaccine Study for High Risk Cancers NCT00944580 | Penn State University | Phase 1 |
| Completed | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma NCT00668148 | Eli Lilly and Company | Phase 2 |
| Completed | A Study of Pemetrexed in Children With Recurrent Cancer NCT00520936 | Eli Lilly and Company | Phase 2 |
| Completed | Trial of Dasatinib in Advanced Sarcomas NCT00464620 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Completed | Collecting and Storing Tissue From Young Patients With Cancer NCT00898755 | Children's Oncology Group | — |
| Completed | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer NCT00436657 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma NCT00354835 | Children's Oncology Group | Phase 3 |
| Terminated | HGS-ETR2 to Treat Children With Solid Tumors NCT00428272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors NCT00187174 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma NCT00592592 | Massachusetts General Hospital | N/A |
| Completed | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation NCT01386619 | University Hospital, Basel, Switzerland | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiation Therapy to Treat Musculoskeletal Tumors NCT00186992 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy NCT00187109 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Completed | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy NCT00004853 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Sof NCT00919269 | Children's Oncology Group | — |
| Completed | Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases NCT00001686 | National Cancer Institute (NCI) | — |
| Completed | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation NCT00001564 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After NCT00001566 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood NCT00162695 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and NCT00001335 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children NCT00339118 | Sheba Medical Center | Phase 4 |